Objective: The International League Against Epilepsy (ILAE) has proposed to expand the definition of remission to 10 years seizure-free with the last 5 years off antiepileptic drugs (AEDs). We examined if a 10-year remission is needed to predict the lowest recurrence risk. Methods: The population-based study cohort consisted of 148 patients with new-onset childhood epilepsy living in the catchment area of Turku University Hospital. They were prospectively followed for 44 years (median). Patients in first remission were prospectively followed for the duration of remission or possible relapse at 2 years in remission with the last year without antiepileptic drugs (AEDs), at 5 years in remission with the last 2 years without AEDs, and at 10 years with the last 5 years without AEDs. For comparison of the proportions of relapsed patients within each remission category exact Clopper Pearson 95% confidence intervals were used. Results: The magnitude of the relapse rate estimates off AEDs did not significantly improve when remission increased from 2 years (2YR) to 5 years (5YR) and further to 10 years (10YR). However, 10YR was a more sensitive measure of no relapse than 2YR. Among patients with remission on or off AEDs, the ability to predict lower relapse rate increased markedly from 2 to 5 years, and again from 5 to 10 years. The risk of relapse was virtually the same estimated after 2YR off AEDs as after 10YR on or off AEDs, except for patients with generalized epilepsy whose 2YR off AEDs was a weaker predictor than 10YR on or off AEDs. Significance: Given the modest differences in relapse rates between the 5 years seizure-free with last 2 years off medications definition and the 10 years seizure-free with last 5 years off medications, and the adverse impact of not being considered in remission, we propose that a return to the 5-year definition may be warranted.
The question of when epilepsy can be considered in remission is a challenging one. Outside of isolated age-specific epilepsy syndromes such as benign epilepsy of childhood with centrotemporal spikes (BECTS), [1] [2] [3] can one ever really be sure that epilepsy will not recur? For many reasons including driving, employment in certain occupations, insurability, and so on, criteria for and estimates of the risk of recurrence are crucially needed, because these issues have a significant impact on people with epilepsy and their families. In most studies, so far, be they epidemiologic outcome studies, [4] [5] [6] [7] studies of discontinuing antiepileptic drugs (AEDs) in remission on AEDs, 8, 9 or following epilepsy surgery, 10-13 either a 2-or 5-year seizure-free definition of remission on or off AEDs was used. More recently, the International League Against Epilepsy (ILAE) has proposed to expand the definition to 10-year seizure-free, of which at least the last 5 years are off AEDs. 14 This definition is based, however, on a consensus of expert opinion, as there are few published data with 10-year seizure-free outcomes available. 15 There are hardly any reports on 10-year terminal remission. Callenbach et al. 16 followed a cohort of 29 children with newly diagnosed BECTS. After 12-17 years of follow-up, 96% had entered 5-year and 89% 10-year terminal remission. Information about whether the subjects were on or off AEDs was not provided. Berg et al. 17 reported that 5-and 10-year remission, regardless of continued treatment, occurred more often in children with absence epilepsy who were initially treated with ethosuximide versus valproate. In a study of 10-year remission including 5 years off AEDs, Berg et al. 18 found 5-year remission off AEDs to be a meaningful but not absolute marker for continued remission.
But how long does one have to wait before considering epilepsy to be remitted? The lack of compelling evidence on this clinically relevant question prompted our study. More specifically, we addressed whether a remission of 2 years with at least 1 year off AEDs, 5 years with at least the last 2 years off AEDs or, as proposed by Fisher et al., 14 10 years with at least the last 5 years off AEDs is needed to predict the lowest recurrence risk. However, there are no observational data on the prognostic value as a predictor of relapse risk for the definition of 10-year remission with the last 5 years without AEDs compared with 5-year remission with the last 2 years without AEDs.
The Turku Adult Childhood Onset Epilepsy (TACOE) study is based on a population cohort of childhood-onset epilepsy that has been followed prospectively for 50 years. 7, 19 This evidence provides a unique opportunity to compare the robustness of the different definitions of remission. Our purpose was to study whether the accuracy of prediction of seizure-free future increases when the duration of preceding remission is prolonged from 2 to 5 years, and further to 10 years.
Subjects and Methods
The study cohort is described previously in several reports. 6, 7, [19] [20] [21] [22] [23] [24] In brief, the cohort consisted of 245 child patients aged 15 years or less who were living in the catchment area of Turku University Hospital at the end of 1964 and had a diagnosed epilepsy, defined as two or more unprovoked seizures. Patients were either cases of new-onset epilepsy in 1961-1964 (n = 150, incident cases) or had epilepsy diagnosed prior to 1961 and had at least one unprovoked seizure in 1961-1964 (n = 95, prevalent cases). For the present study, the prevalent cases were excluded, and only patients with incident cases were included. Epileptic seizures and syndromes were later reclassified 25 to be in line with the updated ILAE definitions. [26] [27] [28] Children with newonset epilepsy and born in the catchment area of Turku University Hospital were identified by reviewing all relevant files from inpatient and outpatient clinical and electroencephalography (EEG) records of any of the hospitals and institutions in the catchment area of Turku University Hospital and any relevant hospitals or institutions in southern Finland; special schools in the area; and records of community general practitioners' offices and private office. Ninety-one percent of 148 study subjects were seen at the Turku University Hospital, and the remaining 9% at other hospitals and institutions in southern Finland. The rule was -and still is-that every child who starts to have epileptic seizures is to be referred for evaluation. Additional EEG and neuroimaging investigations were performed on clinical grounds, if needed. Finally, to detect those patients not otherwise identified, the National Health Service Register data of reimbursed AEDs for epilepsy were reviewed with permission of the public authorities. The registers of the national social security institution are based on the legislation effective since 1964, with the principles largely copied from the British National Health Service act. The registers have proved to be a reliable source of data for research purposes in many reports. The review of all the above-mentioned records including EEG statements and clinical examinations of the 150 children included in the study was done by one child neurologist (M.S.). Two children died before the end of 3-year follow-up, the minimum required for detecting a 2-year remission period. Thus, 148 subjects remained for the present analysis. Sixty-four children had focal epilepsy, and all but two of the remaining 84 had what used to be called primary generalized. The mean follow-up time was 39.1 years (standard deviation [SD] 10.1, median 44.0, range 6-47 years).
The cohort was followed up regularly every fifth year for seizure status until the end of 2007, death, or emigration, using mainly semi-structured questionnaires. In addition, with the signed permission of the patients, data were also collected from hospital and institution files. Patients who had entered remission were prospectively followed for the duration of remission or possible relapse at 2 years in remission with the last year without AEDs, at 5 years in remission with the last 2 years without AEDs, and at 10 years with the last 5 years without AEDs (later in the text referred to as "2YR," "5YR," and "10YR," respectively). For the present study, only the first remission of 2, 5, and 10 years, respectively, was considered for each patient ( 5-year remission, would also be included in the "5YR" category, and likewise a patient who continued to be in 5YR and later attained 10YR, would be included in the "10YR" category. As a consequence, the 2YR, 5YR, and 10YR groups are not mutually exclusive or independent because the same individual patient may be included in more than one remission period as defined. Patients in remission were regularly advised by M.S. about the risks and benefits of stopping AEDs in remission.
Statistical analysis
As outlined earlier, the remission groups are not independent or mutually exclusive. Subsequently, we cannot use customary statistical tests. For comparison of the different remission categories, we assessed the proportions of relapsed patients within each remission category. Uncertainty of the estimates was controlled for by using exact Clopper Pearson 95% confidence intervals (95% CIs) from the binomial distribution. 29 The rates and their CIs are presented as a forest plot. If the CIs of the estimates were not overlapping, the relapse rates were considered to be distinct between the categories. Kaplan-Meier graphs are given for the cumulative probabilities of time to relapse for the first 2YR, 5YR, and 10YR categories, respectively, with respect to AEDs. The data are given for all 148 patients and separately for the subgroup of 84 patients with generalized epilepsy. Statistical analyses were done with SAS System for Windows, release 9.4 (SAS Institute, Cary, NC, U.S.A.) and R 3.2.2 (R Foundation for Statistical Computing, Vienna, Austria).
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Results
At the median 44-year follow-up, 117 (79%) of 148 subjects were in 5-year remission ever on or off medications and 98 (66%) of 148 subjects in 5-year terminal remission. Table 1 summarizes the number of patients in the different relapse categories and the relapse rates among the 148 incident patients with childhood-onset epilepsy, and the 84 with generalized epilepsy.
Limiting the analysis to those with primary generalized epilepsy did not change the results. About 50% reduction in the relapse rate is seen when the duration of remission increases from 2 to 5 years and, again, from 5 to 10 years, and even more so when the patients remain in remission without AEDs. Being able to discontinue AEDs is a stronger predictor than longer duration of remission in lowering the risk of future relapse. Figure 2A shows the Kaplan-Meier estimates of the cumulative probability of time from achieved remission to relapse and proportions of relapsed patients at first 2-, 5-, and 10-year remissions. When first 2YR, 5YR, or 10YR has been attained, 5 further years of follow-up appear to be enough to reasonably well approximate the risk of relapse ( Fig. 2A) . The shape of the curves remains similar when only patients with generalized epilepsy are considered (Fig. 2B ). Note that due to the study design, patients with late relapse in the shorter remission groups are also included in the longer remission groups. Figure 3 presents the overall relapse risk in the different remission categories during the total follow-up period, when the timing of relapse is not considered. Overlapping of 95% CIs between the remission categories off AEDs meant that the accuracy of the relapse rate estimates did not significantly improve when the time in remission increased from 2 to 5 years and further to 10 years. However, within the 95% CI, 10YR was a more sensitive measure of no relapse than 2YR. Among patients with remission on or off AEDs, the ability to predict lower relapse rate increased markedly when the premise of preceding remission time was raised from 2 to 5 years, and again from 5 to 10 years. Strikingly, the risk of relapse was virtually the same estimated after 2YR off AEDs as after 10YR on or off AEDs, except for those with generalized epilepsy whose 2YR off AEDs was a weaker predictor than 10YR on or off AEDs.
Discussion and Conclusions
Our population-based study of incident childhood-onset epilepsy aimed at determining if there is any relevant difference between the commonly used criteria of either 2-year remission with the last year off AEDs, 5-year remission with the last 2 years off AEDs, or 10-year remission with the last 5 years off AEDs, when predicting whether epilepsy can be considered to remain in remission without relapse.
A well-known U.S. population study 30 retrospectively found 76% of all 457 patients of all ages with incident epilepsy, irrespective of etiology, to have achieved at least one 5-year remission period during 20-year follow-up. The remission was sustained at the end of follow-up in 70%. In a recent retrospective Italian population study of 747 subjects of all ages with either prevalent or incident epilepsy, during follow-up of 20 years, 50% had started a period of 5-year remission and 43% were in sustained or terminal remission. 31 In a recent prospective observational generalpractitioner-based cohort study from the United Kingdom, 32 318 people with incident epilepsy were followed for 25 years. Five-year remission ever was achieved by 81% and 5-year terminal remission by 80% of 178 subjects with complete follow-up. The present remission data of childhood-onset epilepsy are well in line with those of three Kaplan-Meier estimates of the cumulative probability of relapse and proportions of the relapse after the first 2-, 5-, and 10-year remission off AEDs among 148 patients with new-onset childhood epilepsy (A) and among the subgroup of 84 patients with generalized epilepsy (B) during long-term follow-up. Blue lines: 2-year remission with the last year off AEDs; purple lines: 5-year remission with the last 2 years off AEDs; red lines: 10-year remission with the last 5 years off AEDs. Epilepsia ILAE studies with regard to 5-year remission ever (present 79% vs. previously reported 50-81%) or 5-year terminal remission (present 66% vs. previously reported 43-80%). Unlike our study, the U.S., Italian, and United Kingdom studies did not, however, compare 2-, 5-, or 10-year terminal remission rates.
There are three main findings of clinical relevance. First, we might, for the first time, give study-based data on the impact of the 10-year remission with the last 5 years off AEDs on the risk of relapse and compare the results between the previously used definitions of 5-year remission with 2YR off AEDs, and 2YR with the latter off AEDs, respectively. Second, despite the anticipated decrease in relapse risk after longer remission times, the relapse rates differed only between 10YR versus 2YR among patients off AEDs at the end of follow-up for a median 44 years since their first seizure before the age of 16 years. In patients on or off AEDs, a reduction in the relapse rate was seen, however, with increasing duration of remission from 2YR to 5YR and further from 5YR to 10YR. Third, although discontinuation of the AEDs was considered as a better predictor than longer duration of remission in lowering the risk of future relapse, the risk of relapse was not higher, whether predicted by 10YR on or off AEDs than 2YR off AEDs, respectively. This finding is in line with clinical experience that many young adults who have no more seizures and medical indications for continued antiepileptic treatment still want to continue on AEDs, mostly in fear of reemergent seizures and their adverse social consequences.
Taken together, and answering the study question, our data indicate that epilepsy can only be predicted to remain in remission with the lowest risk of relapse on or off AEDs when 10 years have passed without relapse, whereas risk assessment based on 2YR and 5YR is less reliable. However, in patients with remission off AEDs, prolongation of follow-up time from 5 to 10 years did not improve the predictability of relapse risk. The risk is between 10% and 30% for patients on or off AEDs after 10 years remission and between 5% and 20% for patients off AEDs after 5 years in remission.
Although our population-based study has the advantage of a very long median follow-up of 44 years of incident new-onset epilepsy in childhood, it also has its limitations. These include the fact that modern treatment including newer AEDs, relevant surgery, vagus nerve stimulation, or electric therapy was not available for most of the long-term study that began in the 1960s. The relatively small sample size did not permit subgroup analysis of relapse risk. In addition, the study population was limited to childhoodonset epilepsy, and adult-onset epilepsy may not be identical in prognosis. Finally, the decision to remain on treatment was made on clinical grounds and not by a standardized protocol.
Despite limitations, our long-term study has three clinically important implications. First, our study could, for the first time, compare the former and the newly introduced criteria and determine the lowest risk of future relapse in patients entering first remission. This is important for the management and research of epilepsy, as most people with epilepsy fortunately enter remission, 21 ,33 yet we had to rely mostly on expert opinion that was not based on prospective evidence from an ultra-long-term population-based study (see Introduction). Second, our study showed that long-term remission can be predicted after 5-year remission with the last 2 years without AEDs, with no need to wait for the results of 10-year remission. This information is clinically important and supports the results of earlier studies with shorter follow-up studies of remission off AEDs. 17, 34 Third, our study-or any other study-cannot provide absolute criteria for predicting life-time remission, for being seizure-free for 10 years or more even off AEDs may still be followed in a small subpopulation of patients, by redevelopment of seizures after long periods of remission. 33, 35 Furthermore, better recognition and delineation of initial epilepsy through increased awareness and new diagnostic investigations may allow for earlier and more effective treatment that was not available when our study started 50 years ago.
The definition of remission has major implications for patients' perceptions of themselves, employability Forest plot of relapse rates with exact Clopper Pearson 95% confidence intervals for patients in 2-, 5-, and 10-year remission categories. The relapse rates decrease as the duration of remissions gets longer. Nonoverlapping confidence intervals indicate different relapse rates between the remission groups. Epilepsia ILAE especially in certain professions, and potentially on insurability. The traditional definition was based on 5 years. The longer a patient is in remission, the better the chances of remaining so, but that, apart from the age-specific syndromes such as benign epilepsy of childhood with centrotemporal spikes, the rate never goes to zero. Given the very modest differences in relapse rates between the 5 years seizure-free with the last 2 years off medications definition and that of the 10 years seizure-free with the last 5 years off medications, we propose that a return to the 5-year definition, which is supported by multiple prospective studies, may be warranted.
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